Trial of Pregabalin for Acute and Chronic Sciatica

Area of Science:

• Neurology
• Pain Management
• Clinical Pharmacology

Background:

• Sciatica is a disabling condition with limited evidence for effective medical treatments.
• Pregabalin is known to be effective for certain neuropathic pain types.
• The study aimed to investigate pregabalin's potential to alleviate sciatica pain intensity.

Purpose of the Study:

• To evaluate the efficacy of pregabalin in reducing leg pain intensity in patients with sciatica.
• To assess the impact of pregabalin on disability, back pain, and quality of life.
• To compare the safety and tolerability of pregabalin versus placebo over 8 weeks and 1 year.

Main Methods:

• A randomized, double-blind, placebo-controlled trial was conducted.
• Patients received either pregabalin (150-600 mg/day) or placebo for up to 8 weeks.
• Primary outcome: leg-pain intensity score at week 8; secondary outcomes assessed over 1 year.

Main Results:

• No significant difference in leg-pain intensity was found between pregabalin and placebo groups at week 8 (P=0.19) or week 52 (P=0.46).
• Secondary outcomes, including disability and quality of life, also showed no significant improvement with pregabalin.
• Adverse events, particularly dizziness, were significantly more common in the pregabalin group.

Conclusions:

• Pregabalin treatment did not significantly reduce leg pain intensity in sciatica patients compared to placebo.
• No significant improvements in secondary outcomes were observed with pregabalin.
• The incidence of adverse events was higher in the pregabalin group, suggesting a less favorable risk-benefit profile for this indication.